Drug intelligence / Profile preview

GSK856

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Intravenous

Overview

GSK856 is a novel, small-molecule dimeric amidobenzimidazole that acts as a Stimulator of Interferon Genes (STING) agonist. Developed by GSK, it is designed for systemic (intravenous) administration to enhance antitumor immunity by inducing the expression of interferon-stimulated genes (ISGs) and the production of proinflammatory cytokines. In veterinary clinical studies involving dogs with various solid tumors, including malignant melanoma and soft tissue sarcoma, GSK856 demonstrated on-target pharmacodynamic effects and a manageable safety profile, characterized by transient cytokine release consistent with activation of the STING pathway.

Targets

STING (Stimulator of interferon genes protein)

Beyond the preview

Go deeper on GSK856.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK856.

Explore the full profile